ANI Pharma rises on Q3 results beat, FY revenue forecast raise

Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 1.4% to $91.51 premarket

Co reports Q3 revenue of $227.8 million, beating analysts' average estimate of $211.04 million - LSEG-compiled data

ANIP posts Q3 adj. profit of $2.04 per share vs estimates of $1.75 apiece

Co expects 2025 revenue between $854 million and $873 million, compared with earlier projection of $818 million to $843 million; analysts expect annual revenue of $844.68

As of last close, ANIP stock was up 63.2% YTD